[Part I: Financial Information](index=3&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) Part I details the unaudited condensed financial statements, management's discussion and analysis of financial condition, and internal controls and procedures [Financial Statements (Unaudited)](index=3&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) Chavant Capital Acquisition Corp., a shell company, reported its unaudited condensed financial statements for the period ended September 30, 2023. The statements reflect the company's status as a Special Purpose Acquisition Company (SPAC) with no operating revenue. Key elements include a significant reduction in assets due to shareholder redemptions, a net loss for the nine-month period, and liabilities primarily composed of promissory notes, warrant liability, and a PIPE derivative liability. The company faces a going concern issue due to insufficient working capital [Condensed Balance Sheets](index=3&type=section&id=Condensed%20Balance%20Sheets) The balance sheet reflects a significant reduction in assets due to shareholder redemptions and an increasing shareholders' deficit, indicating financial strain Condensed Balance Sheet Summary (Unaudited) | Balance Sheet Items | September 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Assets** | | | | Cash | $7,525 | $175,788 | | Investment held in trust account | $8,676,157 | $9,835,409 | | **Total Assets** | **$8,693,330** | **$10,011,197** | | **Liabilities** | | | | Total Current Liabilities | $2,245,605 | $1,020,257 | | Warrant liability | $79,220 | $335,240 | | PIPE derivative liability | $1,200,538 | $1,065,297 | | **Total Liabilities** | **$3,525,363** | **$2,420,794** | | Ordinary shares subject to possible redemption | $8,576,157 | $9,735,409 | | **Total Shareholders' Deficit** | **($3,408,190)** | **($2,145,006)** | [Condensed Statements of Operations](index=4&type=section&id=Condensed%20Statements%20of%20Operations) The statements of operations show a net loss for the nine-month period, primarily driven by operating costs, partially offset by changes in fair value of liabilities and interest income Condensed Statements of Operations Summary (Unaudited) | Operations Data | Three months ended Sep 30, 2023 | Nine months ended Sep 30, 2023 | | :--- | :--- | :--- | | Loss from operations | ($239,376) | ($1,010,314) | | Change in fair value of warrant liability | $57,120 | $256,020 | | Interest and dividend earned on trust account | $88,700 | $313,506 | | Change in fair value of PIPE derivative liability | $87,680 | ($135,241) | | **Net (Loss) Income** | **($5,876)** | **($576,029)** | [Condensed Statements of Changes in Shareholders' Deficit](index=5&type=section&id=Condensed%20Statements%20of%20Changes%20in%20Shareholders'%20Deficit) The statements illustrate a growing shareholders' deficit, primarily due to net losses and substantial share redemptions over the period - As of September 30, 2023, the company had **778,912 ordinary shares** subject to possible redemption, a significant decrease from **8,000,000** at the beginning of 2022 due to multiple redemption events[14](index=14&type=chunk) - The total shareholders' deficit increased from **($2,145,006)** at the beginning of 2023 to **($3,408,190)** by September 30, 2023, driven by net losses and adjustments for share redemptions[14](index=14&type=chunk) [Condensed Statements of Cash Flows](index=6&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) Cash flow analysis reveals significant cash used in financing activities for share redemptions, partially offset by proceeds from sponsor promissory notes Condensed Statements of Cash Flows Summary (Unaudited) | Cash Flow Data (Nine months ended Sep 30) | 2023 | 2022 | | :--- | :--- | :--- | | Net cash used in operating activities | ($343,459) | ($428,146) | | Net cash provided by (used in) investing activities | $1,333,604 | $70,478,927 | | Net cash used in financing activities | ($1,158,408) | ($70,211,278) | | **Net Change in Cash** | **($168,263)** | **($160,497)** | | **Cash - End of period** | **$7,525** | **$80,209** | - For the nine months ended September 30, 2023, cash used in financing activities included **$1,846,408** for the redemption of ordinary shares, partially offset by **$688,000** in proceeds from a promissory note from the sponsor[17](index=17&type=chunk) [Notes to Condensed Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Financial%20Statements) The notes detail the company's formation as a SPAC, its proposed business combination with Mobix Labs, and significant financial events. Key disclosures include the terms of the Mobix Labs transaction, multiple extensions of the business combination deadline accompanied by shareholder redemptions, and the resulting Nasdaq non-compliance notices. The company's liquidity is constrained, raising substantial doubt about its ability to continue as a going concern, and it relies on loans from its sponsor for working capital. The notes also explain the accounting for complex financial instruments like warrants and a PIPE derivative liability - The company entered into a business combination agreement with Mobix Labs, Inc. on November 15, 2022. The deal includes a **$30 million PIPE investment** and the outside date for closing was extended to November 22, 2023[23](index=23&type=chunk)[24](index=24&type=chunk)[25](index=25&type=chunk) - The company received delisting notices from Nasdaq for failing to meet the minimum Market Value of Listed Securities (MVLS) and the minimum of 300 public holders. A hearing was held on November 9, 2023, to request an extension to regain compliance[26](index=26&type=chunk)[27](index=27&type=chunk)[28](index=28&type=chunk) - The company has extended its business combination deadline to January 22, 2024. These extensions led to significant redemptions, with shareholders redeeming **7,046,967 shares** in July 2022, **96,991 shares** in January 2023, and **77,130 shares** in July 2023[36](index=36&type=chunk)[37](index=37&type=chunk)[38](index=38&type=chunk) - Management has concluded there is substantial doubt about the Company's ability to continue as a going concern due to significant costs and insufficient cash outside the Trust Account to operate for the next 12 months[53](index=53&type=chunk) - As of September 30, 2023, the company had drawn down a total of **$1,350,000** in working capital loans from its sponsor, consisting of **$1,150,000** in convertible notes and **$200,000** in a non-convertible note[92](index=92&type=chunk) Fair Value of Financial Instruments (as of Sep 30, 2023) | Description | Level | Fair Value | | :--- | :--- | :--- | | **Assets:** | | | | Investments held in Trust Account | 1 | $8,676,157 | | **Liabilities:** | | | | PIPE Derivative Liability | 3 | $1,200,538 | | Warrant Liability | 2 | $79,220 | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's status as a blank check company formed to effect a business combination, focusing on the proposed transaction with Mobix Labs. The analysis covers the results of operations, which reflect a net loss driven by operating costs, and the company's liquidity and capital resources. A key concern highlighted is the company's working capital deficiency and the substantial doubt about its ability to continue as a going concern, which management plans to address through the business combination and continued reliance on sponsor loans [Overview and Proposed Mobix Labs Transaction](index=23&type=section&id=Overview%20and%20Proposed%20Mobix%20Labs%20Transaction) This section provides an overview of the company's SPAC status, the proposed business combination with Mobix Labs, and ongoing Nasdaq compliance challenges - The company is a blank check company that consummated its IPO on July 22, 2021, raising **$80 million**. As of September 30, 2023, after multiple redemptions, the trust account holds **$8,676,157**[127](index=127&type=chunk)[133](index=133&type=chunk) - The company entered into a definitive business combination agreement with Mobix Labs on November 15, 2022. The transaction includes a **$30 million PIPE investment** and is expected to be listed on Nasdaq upon closing[134](index=134&type=chunk)[135](index=135&type=chunk) - The company is not in compliance with Nasdaq's continued listing rules for minimum market value and minimum public holders. It has requested an extension from a Nasdaq Hearings Panel to regain compliance, with a decision pending[137](index=137&type=chunk)[140](index=140&type=chunk)[142](index=142&type=chunk) [Results of Operations](index=25&type=section&id=Results%20of%20Operations) The results of operations show a net loss for the three and nine months ended September 30, 2023, primarily due to operating costs Comparison of Operating Results | Period | Net (Loss) / Income | Key Drivers | | :--- | :--- | :--- | | **Three months ended Sep 30, 2023** | ($6,000) | Operating costs of ~$239k, offset by gains on warrant/PIPE liability and interest income | | **Three months ended Sep 30, 2022** | ($63,000) | Operating costs of ~$293k, partially offset by gains on warrant liability and interest income | | **Nine months ended Sep 30, 2023** | ($576,000) | Operating costs of ~$1.01M and loss on PIPE liability, partially offset by gain on warrant liability and interest income | | **Nine months ended Sep 30, 2022** | $576,000 | Gain on warrant liability of ~$1.53M and interest income, offsetting operating costs of ~$1.1M | [Liquidity and Capital Resources](index=26&type=section&id=Liquidity%20and%20Capital%20Resources) The company faces significant liquidity challenges and a working capital deficiency, relying on sponsor loans to fund operations and the proposed business combination - As of September 30, 2023, the company had only **$7,525** of cash held outside the trust account and a working capital deficiency of **$2,228,432**[150](index=150&type=chunk) - Management has concluded that the limited cash raises substantial doubt about the company's ability to continue as a going concern for the next 12 months. The company is reliant on loans from its sponsor to fund working capital[153](index=153&type=chunk)[154](index=154&type=chunk) - To fund operations and combination deadline extensions, the company has drawn down a total of **$1,350,000** in working capital loans from its sponsor as of September 30, 2023. Up to **$1,500,000** of such loans are convertible into warrants[161](index=161&type=chunk)[168](index=168&type=chunk) [Controls and Procedures](index=29&type=section&id=Item%204.%20Controls%20and%20Procedures) Management evaluated the company's disclosure controls and procedures and concluded they were not effective as of September 30, 2023. This is due to the persistence of material weaknesses identified as of December 31, 2022, related to an insufficient control environment, lack of personnel with adequate accounting knowledge, and specific control deficiencies over complex accounting transactions and third-party valuations. Remediation efforts are underway but are not yet complete - Management concluded that disclosure controls and procedures were **not effective** as of September 30, 2023[178](index=178&type=chunk) - The ineffectiveness is due to material weaknesses, including a lack of sufficient personnel with appropriate accounting knowledge and experience[179](index=179&type=chunk) - Specific material weaknesses exist in controls over: (1) calculation of EPS and cash flow classification, (2) accounting for complex instruments like the PIPE, and (3) the review of third-party valuations[180](index=180&type=chunk) [Part II: Other Information](index=31&type=section&id=PART%20II.%20OTHER%20INFORMATION) Part II addresses critical other information, including significant risk factors and details regarding unregistered equity sales and the use of IPO proceeds [Risk Factors](index=31&type=section&id=Item%201A.%20Risk%20Factors) The primary risk factor highlighted is the potential for Nasdaq to delist the company's securities. The company has received notices of non-compliance for failing to meet the minimum Market Value of Listed Securities (MVLS) and the minimum number of public holders. While a hearing has been held to request an extension, there is no assurance it will be granted or that the company can regain compliance, which could severely limit trading and liquidity of its securities - The company's securities are at risk of being **delisted from Nasdaq** for failure to meet continued listing requirements[187](index=187&type=chunk) - The company received a delisting notice for failing to meet the **$35 million minimum Market Value of Listed Securities (MVLS)** rule and another for not having at least **300 public holders**[188](index=188&type=chunk)[189](index=189&type=chunk) - A hearing was held on November 9, 2023, to request more time to regain compliance, but there is no guarantee an extension will be granted. Delisting would lead to adverse consequences, including reduced liquidity and classification as a "penny stock"[192](index=192&type=chunk)[194](index=194&type=chunk)[196](index=196&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=32&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%2C%20Use%20of%20Proceeds%2C%20and%20Issuer%20Purchases%20of%20Equity%20Securities) This section details the unregistered sale of 3,400,000 Private Warrants to the sponsor and underwriters for $3.4 million, concurrent with the IPO. It also outlines the use of proceeds from the IPO and private placement, noting that after underwriting fees and expenses, $80 million was initially placed in the trust account. Subsequent redemptions in connection with business combination deadline extensions have significantly reduced the trust account balance to $8,676,157 as of September 30, 2023 - Simultaneously with the IPO, the company completed a private sale of **3,400,000 Private Warrants** at **$1.00 per warrant**, generating gross proceeds of **$3,400,000**[198](index=198&type=chunk) - The initial **$80 million** in the trust account has been reduced by redemptions. In total, **7,221,088 Public Shares** have been redeemed for approximately **$72.4 million** across three extension votes[202](index=202&type=chunk) - As of September 30, 2023, the balance in the Trust Account was **$8,676,157**, with **778,912 ordinary shares** remaining subject to redemption[202](index=202&type=chunk)

Table of Contents Chavant Capital Acquisition Corp. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) | 001-40621 | | --- | Cayman Islands 001-40621 98-1591717 (Commission File Number) ...

Company Operations and Financial Status - The Company has not engaged in any operations or generated any revenue to date, functioning as a "shell company" with nominal assets primarily in cash [121]. - As of March 31, 2023, the Trust Account held $9,092,522 in investments and cash, with an additional $105,038 in cash available for working capital [128]. - For the three months ended March 31, 2023, the company reported a net loss of approximately $312,000, driven by operating costs of approximately $462,000 [138]. - As of March 31, 2023, the company had $9,092,522 in investments and cash held in the Trust Account, with a working capital deficiency of $1,435,314 [140]. - The company anticipates that cash held outside of the Trust Account will not be sufficient to operate for at least the next 12 months if a business combination is not completed [143]. - The company has incurred significant costs in pursuit of its acquisition plans, raising substantial doubt about its ability to continue as a going concern [143]. - The company does not have any long-term debt or capital lease obligations, other than the Working Capital Loans described [155]. IPO and Funding - The Company completed its IPO on July 22, 2021, raising gross proceeds of $80 million from the sale of 8 million units at $10.00 per unit [122]. - The company has incurred $1,693,616 in expenses related to the IPO, with the remaining net proceeds deposited into the Trust Account earning interest [127]. - The company issued unsecured convertible promissory notes totaling $1,150,000 to the Sponsor for Working Capital Loans [151]. Proposed Transactions and Acquisitions - The Proposed Mobix Labs Transaction, announced on November 15, 2022, involves a merger with Mobix Labs, with the combined entity expected to be named Mobix Labs, Inc. [130]. - A PIPE investment agreement is part of the Proposed Mobix Labs Transaction, involving the private placement of 3 million shares of Class A Common Stock at $10.00 per share, totaling $30 million [131]. - The Company has evaluated over 80 potential acquisition targets and submitted eight non-binding indications of interest or letters of intent [136]. - The company plans to use funds in the Trust Account to complete its initial business combination and may withdraw interest to pay taxes [141]. - The company has extended the deadline for consummating an initial business combination to July 22, 2023, following shareholder approvals [149]. Compliance and Regulatory Issues - The Company received a notice from Nasdaq on March 23, 2023, regarding non-compliance with the minimum Market Value of Listed Securities requirement of $35 million [133]. - The deadline to regain compliance with Nasdaq's MVLS Rule is September 19, 2023, after which the Company may face delisting [135]. - As of March 31, 2023, the company had drawn down $962,000 of Working Capital Loans under promissory notes, with an additional $188,000 available [154].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____ TO _____ COMMISSION FILE NUMBER 001-40621 CHAVANT CAPITAL ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands 98-1 ...

PART I. FINANCIAL INFORMATION [Financial Statements (Unaudited)](index=3&type=section&id=Item%201.%20Financial%20Statements%20%28Unaudited%29) Unaudited Q3 2022 financial statements show significant asset reduction from share redemptions, a net loss, and a subsequent business combination agreement with Mobix Labs [Condensed Balance Sheets](index=3&type=section&id=Condensed%20Balance%20Sheets) Total assets significantly decreased to $9.75 million by September 30, 2022, primarily due to shareholder redemptions from the trust account Condensed Balance Sheet Comparison (Unaudited) | Account | Sep 30, 2022 | Dec 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash | $80,209 | $240,706 | | Investment held in trust account | $9,672,901 | $80,002,777 | | **Total Assets** | **$9,753,110** | **$80,676,074** | | **Liabilities & Equity** | | | | Warrant liability | $136,000 | $1,667,262 | | Total Liabilities | $810,508 | $1,736,264 | | Ordinary shares subject to possible redemption | $9,572,901 | $80,000,000 | | Total Shareholders' Deficit | ($630,299) | ($1,060,190) | [Condensed Statements of Operations](index=4&type=section&id=Condensed%20Statements%20of%20Operations) Q3 2022 saw a net loss of $63,074, a reversal from 2021 net income, primarily due to warrant liability fair value changes Statement of Operations Highlights (Unaudited) | Metric | Q3 2022 | Q3 2021 | Nine Months 2022 | Nine Months 2021 | | :--- | :--- | :--- | :--- | :--- | | Loss from operations | ($292,902) | ($362,248) | ($1,104,243) | ($410,235) | | Gain from change in fair value of warrant liability | $119,000 | $1,156,000 | $1,531,262 | $1,156,000 | | Interest earned on trust account | $110,828 | $789 | $149,051 | $789 | | **Net Income (Loss)** | **($63,074)** | **$794,541** | **$576,070** | **$746,554** | [Condensed Statements of Cash Flows](index=6&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) Net cash decreased by $160,497 for the nine months ended September 30, 2022, driven by significant cash outflows for ordinary share redemptions - The most significant cash flow event was the redemption of ordinary shares, with **$70.57 million** withdrawn from the Trust Account and paid to shareholders[18](index=18&type=chunk) Cash Flow Summary (Nine Months Ended Sep 30, 2022) | Cash Flow Activity | Amount | | :--- | :--- | | Net cash used in operating activities | ($428,146) | | Net cash from investing activities | $70,478,927 | | Net cash from financing activities | ($70,211,278) | | **Net Change in Cash** | **($160,497)** | [Notes to Financial Statements](index=7&type=section&id=Notes%20to%20Financial%20Statements) Notes detail SPAC formation, July 2022 share redemptions, going concern doubts due to limited cash, and the November 2022 Mobix Labs business combination - On July 14, 2022, shareholders approved extending the business combination deadline to January 22, 2023 In connection with this, shareholders holding **7,046,967 shares** redeemed them for approximately **$70.6 million**[28](index=28&type=chunk) - The company's cash of **$80,209** held outside the Trust Account is not sufficient to operate for the next 12 months, raising **substantial doubt** about its ability to continue as a going concern[41](index=41&type=chunk) - On **November 15, 2022**, the company entered into a definitive business combination agreement with **Mobix Labs, Inc** The transaction is expected to close in the first half of 2023[106](index=106&type=chunk) - To fund working capital, the Sponsor has provided loans, with **$362,000** drawn as of September 30, 2022, and an additional **$200,000** drawn in October 2022[84](index=84&type=chunk)[105](index=105&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=19&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) As a blank check company, it reported a Q3 2022 net loss and faces going concern doubts due to limited cash, with a Mobix Labs business combination pending - The company is a **'shell company'** formed for the purpose of effecting a business combination and has not engaged in any operations or generated revenue to date[110](index=110&type=chunk) - On **November 15, 2022**, the company entered into a business combination agreement with **Mobix Labs, Inc.**, which is expected to close in the first half of 2023[118](index=118&type=chunk) - The company's limited cash of **$80,209** and working capital deficiency of **$730,299** as of September 30, 2022, raise **substantial doubt** about its ability to continue as a going concern for the next 12 months[131](index=131&type=chunk) - To fund operations, the company has drawn down **$562,000** under Working Capital Loans from its Sponsor as of November 17, 2022[130](index=130&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=23&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is a smaller reporting company and is not required to provide information for this item - As a **smaller reporting company** defined by Rule 12b-2 of the Exchange Act, the company is not required to provide the information otherwise required under this item[141](index=141&type=chunk) [Controls and Procedures](index=23&type=section&id=Item%204.%20Controls%20and%20Procedures) Disclosure controls were ineffective as of September 30, 2022, due to a material weakness in earnings per share presentation, with a remediation plan underway - Disclosure controls and procedures were deemed **not effective** as of **September 30, 2022**[143](index=143&type=chunk) - The ineffectiveness was due to a **material weakness** in internal control over financial reporting concerning the presentation of earnings per share[143](index=143&type=chunk) - Management plans to remediate the weakness by enhancing processes and increasing communication with accounting professionals[144](index=144&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=24&type=section&id=Item%201.%20Legal%20Proceedings) The company has reported no legal proceedings - There are **no legal proceedings** to report[147](index=147&type=chunk) [Risk Factors](index=24&type=section&id=Item%201A.%20Risk%20Factors) Key risks include a new 1% excise tax on redemptions, potential investment company classification, and possible CFIUS review impacting the Mobix Labs business combination - The company may be subject to a **new 1% non-deductible U.S. federal excise tax** on stock redemptions occurring after December 31, 2022, under the Inflation Reduction Act of 2022, which could reduce cash available for a business combination[148](index=148&type=chunk) - There is a risk of being deemed an **investment company** under the **Investment Company Act**, particularly if a business combination is not completed within 24 months of the IPO To mitigate this, the company may liquidate securities in its Trust Account and hold cash, which would reduce returns for shareholders[150](index=150&type=chunk)[153](index=153&type=chunk) - The proposed business combination with **Mobix Labs** may be subject to review by **CFIUS** due to the Sponsor's substantial ties to non-U.S. persons A CFIUS review could delay, modify, or prevent the transaction[156](index=156&type=chunk)[157](index=157&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=26&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company sold 3.4 million private placement warrants for $3.4 million, with proceeds deposited into a trust account, reduced to $9.67 million after July 2022 redemptions - Simultaneously with the IPO, the company sold **3,400,000 Private Placement Warrants** at **$1.00 per warrant**, raising **$3,400,000** in a private sale exempt from registration[160](index=160&type=chunk) - Gross proceeds of **$80,000,000** from the IPO and proceeds from the warrant sale were placed in a trust account[159](index=159&type=chunk)[162](index=162&type=chunk) - In July 2022, **$70,573,278** was paid out of the trust account to redeem **7,046,967 ordinary shares**, leaving a balance of **$9,672,901** in the trust account as of September 30, 2022[163](index=163&type=chunk) [Defaults Upon Senior Securities](index=27&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company has reported no defaults upon senior securities - **None**[164](index=164&type=chunk) [Mine Safety Disclosures](index=27&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - **Not applicable**[165](index=165&type=chunk) [Other Information](index=27&type=section&id=Item%205.%20Other%20Information) The company has reported no other information - **None**[166](index=166&type=chunk) [Exhibits](index=28&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Quarterly Report on Form 10-Q, which include certifications by the Principal Executive Officer and Principal Financial Officer as required by the Sarbanes-Oxley Act, and Inline XBRL documents - The exhibits filed include **CEO and CFO certifications** (Exhibits 31.1, 31.2, 32.1, 32.2) and Inline XBRL data files (Exhibits 101 and 104)[170](index=170&type=chunk) Signatures - The report was duly signed on **November 17, 2022**, by **Michael Lee, the Chief Financial Officer**[173](index=173&type=chunk)[175](index=175&type=chunk)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Chavant Capital Acquisition Corp. (Exact name of registrant as specified in its charter) | Cayman Islands | 001-40621 | 98-1591717 | | --- | --- | --- | | (State or other j ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Chavant Capital Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-40621 98-1591717 (State or other jurisdiction of incorporation) ...

Table of Contents OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____ TO _____ COMMISSION FILE NUMBER 001-40621 CHAVANT CAPITAL ACQUISITION CORP. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Cayman Islands 98-1 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Chavant Capital Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 001-40621 98-1591717 (State or other jurisdiction of incorporat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR Identification No.) 445 Park Avenue,9th Floor New York, NY 10022 (Address of principal executive offices, including zip code) Registrant's telephone number, including area code: (212) 745-1086 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...